SEC 13F Intelligence

Rhenman & Partners Asset Management AB / JAZZ

Rhenman & Partners Asset Management AB’s Jazz Pharmaceuticals PLC Position

Does Rhenman & Partners Asset Management AB own Jazz Pharmaceuticals PLC (JAZZ)? Yes — 75.9K shares worth $14M (+1.77% of its 13F portfolio) as of Q1 2026, up from 74.0K shares the prior filed quarter.

Position Value
$14M
Q1 2026
Shares
75.9K
% of Portfolio
+1.77%
Quarters Held
30
currently held

Position History JAZZ

Reported value by quarter
Q4 ’18: $21MQ4 ’18Q1 ’19: $27MQ2 ’19: $27MQ3 ’19: $19MQ4 ’19: $15MQ4 ’19Q1 ’20: $12MQ2 ’20: $15MQ3 ’20: $24MQ4 ’20: $36MQ4 ’20Q1 ’21: $41MQ2 ’21: $39MQ3 ’21: $36MQ4 ’21: $37MQ4 ’21Q1 ’22: $28MQ2 ’22: $25MQ3 ’22: $19MQ4 ’22: $20MQ4 ’22Q1 ’23: $22MQ2 ’23: $18MQ3 ’23: $19MQ4 ’23: $15MQ4 ’23Q1 ’24: $18MQ2 ’24: $12MQ3 ’24: $10MQ4 ’24: $18MQ4 ’24Q1 ’25: $15MQ2 ’25: $12MQ3 ’25: $13MQ4 ’25: $13MQ4 ’25Q1 ’26: $14Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 202675.9K$14M+1.77%
Q4 202574.0K$13M+1.18%
Q3 202595.0K$13M+1.39%
Q2 2025109.0K$12M+1.46%
Q1 2025124.3K$15M+1.77%
Q4 2024145.5K$18M+1.84%
Q3 202493.0K$10M+0.84%
Q2 2024114.0K$12M+1.17%
Q1 2024146.7K$18M+1.67%
Q4 2023123.6K$15M+1.52%
Q3 2023143.6K$19M+2.00%
Q2 2023145.0K$18M+1.89%
Q1 2023150.0K$22M+2.39%
Q4 2022128.0K$20M+2.13%
Q3 2022131.5K$19M+1.98%
Q2 2022160.0K$25M+2.84%
Q1 2022182.0K$28M+2.79%
Q4 2021290.0K$37M+2.47%
Q3 2021280.0K$36M+2.56%
Q2 2021220.0K$39M+2.65%
Q1 2021250.0K$41M+2.87%
Q4 2020220.0K$36M+2.96%
Q3 2020170.0K$24M+2.16%
Q2 2020137.0K$15M+1.63%
Q1 2020120.0K$12M+1.68%
Q4 2019100.8K$15M+1.65%
Q3 2019150.0K$19M+2.41%
Q2 2019187.2K$27M+2.94%
Q1 2019187.2K$27M+3.13%
Q4 2018165.8K$21M+2.35%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Rhenman & Partners Asset Management AB’s full portfolio or all institutional holders of JAZZ.